←Back to News & Press releases New publication with TLA confirms a significant reduction of severe exacerbations and increased Quality of Life for patients with severe allergic asthma

New publication with TLA confirms a significant reduction of severe exacerbations and increased Quality of Life for patients with severe allergic asthma

March 15, 2021

Airsonett announced today a new publication: “Effect of nocturnal Temperature-controlled Lami-nar Airflow on the reduction of severe exacerbations in patients with severe allergic asthma: a meta-analysis”1

The study concludes that nocturnal use of TLA (Temperature-controlled Laminar Airflow) shows a beneficial effect on severe exacerbations and quality of life in more symptomatic patients with severe allergic asthma. The patient group with the most severe symptoms showed a significant reduction of severe exacerbations of 48-59%, for TLA compared to placebo.

Professor Leif Bjermer, a co-author, said: "With this publication, we have further confirmed what previous studies have shown; that TLA treatment has a very good effect on both exacerbations and quality of life for multi-sensitised allergic asthma patients that are sensitive to biological stress, with symptoms that are otherwise difficult to control".

"We are indeed pleased with the results of the study, that further confirms the excellent effects on our patient group. Another important take away from this study is that TLA has a particularly good effect on patients with more severe symptoms. This relatively small patient group repre-sents approximately 40% of asthma treatment costs in health care. We can conclude that this fur-ther positions TLA as a very cost-efficient treatment, "says Anders Due-Boje, CEO of Airsonett.

Method of the study: Patients with severe allergic asthma (GINA 4/5) were extracted from two 1-year randomised, double-blind, placebo-controlled trials conducted with TLA. A meta-analysis of the effect on severe exacerbations was performed by negative binomial regression in a sequential manner, defined by baseline markers of asthma control (symptoms and QoL scores).

1: A. J. Chauhan, T. P. Brown, W. Storrar, L. Bjermer, G. Eriksson, F. Radner, S. Peterson & J. O. Warner, European Clinical Respiratory Journal, 10 Mar 2021
2: Clinical documentation for TLA: https://airsonett.eu/clinical-evidence/


For more information:
Anders Due-Boje, CEO, Airsonett AB
Phone: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu


About severe, uncontrolled asthma
Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed, and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is an effective treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.


About Airsonett
Airsonett® is a Swedish medical device company that leads the way in the development of non-pharmacologic treatment of allergic severe asthma and eczema. Airsonett® Air4 is a non-invasive device for treatment in the home, based on the patented Temperature-controlled Laminar Airflow technology (TLA). Treatment with the Airsonett® Air4 significantly reduces allergens and other airborne irritants from the patient’s breathing zone during rest and sleep. Airsonett® Air4 is a CE marked class 1 medical device intended to be used for the alleviation of symptoms of allergy-induced diseases such as allergic asthma and eczema. It adheres to relevant EU directives regarding design, function, safety and health requirements and has undergone rigorous clinical research as well as health-economic studies. Airsonett® Air4 holds a 510(k) cleared class II approval from FDA. The company’s main shareholders are SEB Venture Capital, Industrifonden and Magnus Lundberg. For more information visit www.airsonett.eu



1: Effect of a novel temperature-controlled laminar airflow device on personal breathing zone aeroallergen exposure.
Gore RB, Boyle RJ, Gore C, Custovic A, Hanna H, Svensson P, Warner JO.
Indoor Air. 2015 Feb;25(1):36-44. doi: 10.1111/ina.12122. Epub 2014 Jun 10.
PMID: 24750266

2: Temperature-controlled laminar airflow (TLA) device in the treatment of children with severe atopic eczema: Open-label, proof-of-concept study.
Gore C, Gore RB, Fontanella S, Haider S, Custovic A.
Clin Exp Allergy. 2018 May;48(5):594-603. doi: 10.1111/cea.13105. Epub 2018 Mar 13.
PMID: 29383776